Dr. Antonino Carbone
Professor of Pathology, Former Chairman of Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Italy
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
49Years (1978-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 October 2018 in The Lancet Oncology
Journal Article
VGViviana Galimberti
Viviana GalimbertiBCBernard F Cole
Bernard F Cole
GVGiuseppe Viale
Giuseppe Viale
PVPAOLO VERONESI
PAOLO VERONESIEVElisa Vicini
Elisa Vicini
MTM. Thorburn
M. Thorburn
+194
5 February 2009 in Blood
Journal Article
Antonino CarboneECEthel Cesarman
Ethel Cesarman
MSMichele Spina
Michele Spina
Annunziata GloghiniTSThomas Schultz
Thomas SchultzAmong the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system). Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)–associated multicentric Castleman disease. These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells. EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression. The current knowledge about HIV-associated lymphomas can be summarized in the following key points: (1) lymphomas specifically occurring in patients with HIV infection are closely linked to other viral diseases; (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols in-corporating anticancer treatments and antiretroviral drugs.
28 May 2002 in Neurology
Journal Article
AFAndrés José María Ferreri
Andrés José María FerreriMRM. Reni
M. Reni
FPF. Pasini
F. Pasini
ACA. Calderoni
A. Calderoni
UTU. Tirelli
U. Tirelli
Jaen-Yves Blay +16
Objective: To characterize the therapeutic variables correlated to outcome in 370 patients with primary CNS lymphoma. Methods: Planned treatment was radiotherapy (RT) in 98 patients, chemotherapy (CHT) in 32, RT followed by CHT in 36, and CHT followed by RT in 197 patients. High-dose methotrexate (HD-MTX; 1 to 8 g/m2) was used in 169 patients and intrathecal CHT in 109. Results: One hundred sixteen patients are alive (median follow-up 24 months), with a 2-year overall survival of 37%. Patients treated with CHT followed by RT had improved survival with respect to patients treated with RT alone. Patients receiving HD-MTX–based primary CHT survived longer than those treated with other drugs. HD-MTX associated with other cytostatics, in particular HD-cytarabine, produced better results than HD-MTX alone. No correlation between MTX dose and survival was found. In patients receiving HD-MTX, consolidation RT or intrathecal CHT did not improve survival. Age, performance status, lactate dehydrogenase serum level, CSF protein level, site of disease, and use of HD-MTX were all predictors of survival. Conclusions: Combination CHT-RT is superior to RT alone. Patients treated with primary CHT containing HD-MTX exhibited improved survival. In these patients, the addition of HD-cytarabine was associated with a better survival, whereas intrathecal CHT was not correlated to outcome. RT may be unnecessary in patients achieving complete remission after receiving HD-MTX–based primary CHT.
1 February 2009 in The American Journal of Pathology
Journal Article
MMMaria Paola Martelli
Maria Paola Martelli
GSgabriella sozzi
gabriella sozzi
Luis HernándezVPValentina Pettirossi
Valentina Pettirossi
ANAlba Navarro
Alba NavarroBrunangelo Falini
Brunangelo Falini +16
12 December 2019 in Nature Reviews Disease Primers
Journal Article
Antonino CarboneSRSandrine Roulland
Sandrine Roulland
AGAnnunziata Gloghini
Annunziata Gloghini
AYAnas Younes
Anas Younes
GKGottfried von Keudell
Gottfried von Keudell
JFJude Fitzgibbon
Jude Fitzgibbon
+1
19 April 2010 in The Journal of Pathology
Journal Article
Donatella AldinucciAnnunziata GloghiniAPAntonio Pinto
Antonio Pinto
RFRosaria De Filippi
Rosaria De Filippi
Antonino CarboneAbout Me
Prof. Antonino Carbone
Overall Track Record
Qualifications.
−2014– Professor of Pathology (Professore di prima fascia), Acknowledged by the Ministry of University (MIUR), Italy.
Professional appointments.
−2015-2024 Research Consultant, Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Italy.
−2010-2014 Chairman, Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Italy.
− 2005-2009 Chairman, Department of Pathology, FondazioneIRCCS Istituto Nazionale Tumori, Milano, Italy.
− 1996-2004 Scientific Director, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Italy.
Current International appointments.
− Chairman Italian TNM Staging Committee UICC
− EORTC Pathobiology Group Scientific Board Member and Chairman of the Hematology subgroup
− Editor-in-Chief of Hemato. International Open Access Journal of Hematology
Contribution to the field of research
− The fields of main interest are Hodgkin and non-Hodgkin lymphomas, in particular HIV-associated lymphomas. He contributed to the latter field of research studying and improving the morphologic classification of HIV-associated lymphomas and their viral association. The study of microenvironment impact on lymphomagenesis is the recent contribution to these fields of interest. Member of WHO IARC Monograph Working Group on Biological Agents, Lyon
H-index: 87 (Scopus)